Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04437706 · ClinicalTrials.gov registry record
Network-Targeted Strategies for Efficient Community SARS-CoV-2 (COVID-19) Sampling
A clinical trial of COVID-19 and SARS-CoV-2, sponsored by Duke University.
- Completed
- Registry status
- 602
- Enrollment target
- 1
- Study location
NCT04437706: Completed study of COVID-19 and SARS-CoV-2, sponsored by Duke University.
NCT04437706 is a study of COVID-19 and SARS-CoV-2 that has completed, run by Duke University. The registered enrollment target is 602 participants, below the 38,463-participant average among 298 other COVID-19 trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04437706, a study of COVID-19 and SARS-CoV-2, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 602 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective is to use "network targeted sampling design" to detect active and/or undiagnosed cases of COVID-19 in the community and determine the spread or distribution of 1) active infection, and 2) past exposure. The hypothesis is that there are many undiagnosed and/or asymptomatic people in the community who may be unknowingly spreading the virus or have been exposed and have antibodies. We propose to implement respondent-driven sampling (RDS) which leverages effort on the part of seed or index cases to recruit contacts for participation.
Primary Outcome
Number of participants with active COVID-19 infection
Conditions Studied
Study Locations (1)
North Carolina
- Margaret Pendzich - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 602 participants |
| Start Date | 2020-12-11 |
| Est. Completion | 2022-07-25 |
What the finished NCT04437706 record still lists
NCT04437706 is an observational study that tracks outcomes without assigning an intervention. The registered 602 participants enrollment target is mid-sized for trials with a published cap, below the 38,463-participant average among 298 other COVID-19 trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 0 interventions.
NCT04437706 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT04437706 about?
NCT04437706 is a clinical study titled "Network-Targeted Strategies for Efficient Community SARS-CoV-2 (COVID-19) Sampling". The primary objective is to use "network targeted sampling design" to detect active and/or undiagnosed cases of COVID-19 in the community and determine the spread or distribution of 1) active infection, and 2) past exposure. The hypothesis is that there are many undiagnosed and/or asymptomatic peopl...
What is the current status of trial NCT04437706?
This trial is currently completed. The enrollment target is 602 participants. The study started on 2020-12-11. Estimated completion is 2022-07-25.
What conditions does trial NCT04437706 study?
This clinical trial studies the following conditions: COVID-19, SARS-CoV-2.
Who is sponsoring clinical trial NCT04437706?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04437706 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04437706's enrollment target sits among peer trials
602 99th of 298 higher than 200 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03849443 · 604 participants · Early Phase 1
Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery
- NCT05238922 · 604 participants · Phase 1
Study of INCB123667 in Subjects With Advanced Solid Tumors
- NCT06040541 · 604 participants · Phase 1
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI